International URBAN ARCH Center Grants

Main Grants | Supplements | Affiliated Grants | URBAN ARCH Consortium Grants

Project Number PI/Project Lead Project Dates

Main Grant

The International URBAN Alcohol Research Collaboration on HIV/AIDS (ARCH) Center
The International Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Center will generate new generalizable knowledge about the complex relationship between TB, HIV, and alcohol use in order to accelerate the future development of interventions that can reduce alcohol’s impact on TB-related morbidity and mortality among people with HIV.
P01AA029541 Samet 9/10/21 – 8/31/26


Administrative Core
The Admin Core will accomplish the following Specific Aims: 1) Promote a collaborative, synergistic approach to research goals; 2) Facilitate communication, integration, and collaboration between all Center components; 3) Coordinate access to resources including the International URBAN ARCH Center data and sample repository; 4) Assess and foster components’ progress and quality to maximize the scientific impact of the Center; 5) Encourage the sharing of data with investigators within the Center and beyond; and 6) Develop future leadership of the Center and the next generation of HIV/alcohol researchers.
Samet 9/10/21 – 8/31/26
Biostatistics and Data Management Resource Core
The Biostatistics and Data Management (BDM) Core will play a pivotal role in the International URBAN Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Center as a full collaborator in study design, conduct, data management and statistical analyses. The overarching goal of the BDM Core is to facilitate the long-term conduct of rigorous, reproducible and innovative alcohol/HIV research.
Cheng 9/10/21 – 8/31/26
The Role of Alcohol Use in Incident TB Infection and Active TB Disease Among Persons Living with HIV
This study will examine the risk of acquiring TB infection and of incident active TB disease among people with HIV with heavy alcohol use after receipt of TB preventive therapy (TPT) in people with HIV in Uganda, a high HIV/TB country. The goal of this study is to inform interventions to reduce the risk for acquiring new TB infection in this group, including behavioral interventions to reduce alcohol use, and TPT strategies, such as repeat short-course TPT to prevent active TB disease.
Hahn 9/10/21 – 8/31/26
The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV
This 18- month observational study of 200 people with HIV completing pulmonary TB treatment in Mbarara, Uganda will investigate hazardous drinking (Alcohol Use Disorders Identification Test [AUDIT] ≥8) as a modifiable risk factor for post-TB lung disease in people with HIV.
So-Armah 9/10/21 – 8/31/26


Administrative Supplement
This administrative supplement provided additional funds to support the transition of the TALC project to Mbarara, Uganda.
P01AA029541-02S1 Samet 9/1/22-8/31/26
The TB HIV Aging in Uganda 50-over-50 (THAU 50/50) Study
The THAU 50/50 study will utilize the existing infrastructure of the TALC study to 1) characterize frailty, social vulnerability, and health priorities for older PWH; 2) determine the association of alcohol use with frailty among PWH and how aging and TB modify this relationship; and 3) examine how aging and TB impact social vulnerability.
P01AA029541-03S1 Samet, So-Armah 9/1/23-8/31/24

Affiliated Grants

Biomarkers for Alcohol/HIV Research (BAHR) Study
This project will leverage several research studies of people with HIV that measured phosphatidylethanol (PEth), a biomarker of how much alcohol someone has consumed over the past month that is found in the blood, to investigate key questions about how alcohol use affects the health of persons with HIV and how to reduce alcohol use. We will also use these data to explore other ways to measure alcohol use via common blood tests.
R01AA029962 Hahn 5/01/22-2/28/25
Gabapentin to Reduce Alcohol and Improve Viral Load Suppression – Promoting “Treatment as Prevention”
The GRAIL trial will assess the efficacy of gabapentin versus placebo for improving HIV viral load suppression among people with HIV and heavy alcohol use on ART as a “Treatment as Prevention” strategy. If shown to be effective, this will be a potent addition to the HIV prevention toolkit to address HIV transmission from people with HIV with heavy alcohol use.
R01AA030460 Samet, Lunze 9/20/22-6/30/27